1142224-55-2

Upstream product

• 153580-03-1 5,5-dimethylcyclopent-1-en-1-yl trifluoromethanesulfonate 
• 29415-97-2 methyl 3-bromo-4-hydroxybenzoate 
• 14348-41-5 3-bromo-4-hydroxy-benzoic acid 
• 1142224-45-0 methyl 3-(5,5-dimethylcyclopent-1-enyl)-4-(trifluoromethylsulfonyloxy)benzoate 
• 1142224-42-7 methyl 3-(5,5-dimethylcyclopent-1-enyl)-4-(tetrahydro-2H-pyran-2-yloxy)benzoate 
• 1142224-41-6 methyl 3-bromo-4-(tetrahydro-2H-pyran-2-yloxy)benzoate 
• 4541-32-6 2,2-dimethylcyclopentanone 
• 1011531-89-7 2-(5,5-dimethylcyclopent-1-en-1-yl)-4,4,5,5-tetramethyl-1 ,3 ,2-dioxaborolane 
• 1142224-47-2 methyl 2-(5,5-dimethylcyclopent-1-en-1-yl)-2'-fluoro-5'-methoxy-[1,1'-biphenyl]-4-carboxylate 
• 1142224-50-7 methyl 2-(2,2-dimethylcyclopentyl)-2'-fluoro-5'-(methyloxy)-1,1'-biphenyl-4-carboxylate 
• 1142224-51-8 (2-((1R)-2,2-dimethylcyclopentyl)-2'-fluoro-5'-(methyloxy)-1,1'-biphenyl-4-yl)methanol 
• 1142224-43-8 methyl 3-(5,5-dimethylcyclopent-1-enyl)-4-hydroxybenzoate 

Downstream Products

• 1142224-59-6 4-(chloromethyl)-2-((1R)-2,2-dimethylcyclopentyl)-2'-fluoro-5'-(methyloxy)-1,1'-biphenyl 
• 1222088-90-5 AM-5262 
• 1435275-53-8 (1R,2R)-7'-((2-((R)-2,2-dimethylcyclopentyl)-2'-fluoro-5'-methoxy-[1,1'-biphenyl]-4-yl)methoxy)-3',4'-dihydro-2'H-spiro[cyclopropane-1,1'-naphthalene]-2-carboxylic acid 
• 1435275-59-4 (1R,2R)-7'-((2-((R)-2,2-dimethylcyclopentyl)-2'-fluoro-5'-methoxy-[1,1'-biphenyl]-4-yl)methoxy)-8'-fluoro-3',4'-dihydro-2'H-spiro[cyclopropane-1,1'-naphthalene]-2-carboxylic acid 
• 1448668-63-0 C₃₅H₃₉FO₄ 

Relevant academic research and scientific papers

Discovery of AM-6226: A Potent and Orally Bioavailable GPR40 Full Agonist That Displays Efficacy in Nonhuman Primates

GPR40 (FFA1) is a G-protein-coupled receptor, primarily expressed in pancreatic islets and enteroendocrine L-cells, and, when activated, elicits increased insulin secretion only in the presence of elevated glucose levels. We recently reported the discovery of AM-1638 (2), a full agonist of GPR40. Herein, we present further structure-activity relationships progressing from AM-1638 (2) to AM-6226 (14) that possesses a profile acceptable for dosing cynomolgus monkeys. The GPR40 full agonist AM-6226 (14) is the first molecule to display significant glucose lowering in cynomolgus monkeys providing additional evidence that GPR40 full agonists afford access to a powerful mechanism for maintaining glycemic control.

Discovery and optimization of potent GPR40 full agonists containing tricyclic spirocycles

GPR40 (FFAR1 or FFA1) is a target of high interest being pursued to treat type II diabetes due to its unique mechanism leading to little risk of hypoglycemia. We recently reported the discovery of AM-1638 (2), a potent full agonist of GPR40. In this repor

SPIROCYCLIC GPR40 MODULATORS

The present invention provides compounds useful, for example, for treating metabolic disorders in a subject. Such compounds have the general formula IA, IB, I'A or I'B, where the definitions of the variables are provided herein. The present invention also

CONFORMATIONALLY CONSTRAINED CARBOXYLIC ACID DERIVATIVES USEFUL FOR TREATING METABOLIC DISORDERS

The present invention provides compounds useful, for example, for treating metabolic disorders in a subject. Such compounds have the general formula I or the general formula III: where the definitions of the variables are provided herein. The present invention also provides compositions that include, and methods for using, the compounds in preparing medicaments and for treating metabolic disorders such as, for example, type II diabetes.